Skip to main content

Table 2 Subgroup analysis of prognostic value of SIRI for OS and PFS in patients with EC

From: Prognostic and clinicopathological impact of systemic inflammation response index (SIRI) on patients with esophageal cancer: a meta-analysis

Subgroups

No. of studies

No. of patients

Effects model

HR (95%CI)

p

Heterogeneity I2(%) Ph

OS

 Total

5

2125

Fixed

1.43(1.20–1.71)

 < 0.001

48.8

0.098

Sample size

 < 200

2

331

Random

2.86(0.93–8.83)

0.067

64.9

0.091

 ≥ 200

3

1794

Fixed

1.28(1.05–1.57)

0.016

0

0.921

TNM stage

 I-IV

3

1017

Random

1.84(0.74–4.61)

0.192

62.4

0.070

 I-III/II-III/II-IV

2

1108

Random

1.52(1.07–2.14)

0.018

59.6

0.116

Treatment

 Surgery

4

1933

Fixed

1.33(1.09–1.62)

0.005

44.2

0.146

 Radiotherapy/CRT + ICIs

1

192

-

1.88(1.28–2.75)

0.001

-

-

SIRI cut-off value

 < 1.0

2

878

Fixed

1.20(0.78–1.83)

0.408

0

0.871

 ≥ 1.0

3

1247

Random

1.80(1.09–2.95)

0.020

71.2

0.031

Survival analysis

 Univariate

1

139

-

6.26(1.63–24.01)

0.008

-

-

 Multivariate

4

1986

Fixed

1.39(1.17–1.67)

 < 0.001

3.7

0.374

PFS

 Total

2

243

Fixed

2.00(1.35–2.98)

0.001

0

0.409

  1. SIRI systemic inflammation response index, OS overall survival, PFS progression-free survival, CRT chemoradiotherapy, ICIs immune checkpoint inhibitors, EC esophageal cancer